Sanofi Pasteur has purchased Freeslate?s Biologics Formulation System for accelerating research in vaccine and protein formulation development.
Freeslate, a provider of high-throughput research solutions, reports that Sanofi Pasteur, the vaccines division of Sanofi, has purchased Freeslate’s Biologics Formulation System, which is usual in vaccine and protein formulation development. The system automates sample preparation, sample stressing, and formulation analysis, to allow for the development of stable, robust formulations more quickly with reduced API consumption.
Based on the Freeslate Core Module 3 automation platform, the Biologics Formulation System combines liquid dispense and controlled heating/cooling/mixing with new automated measurements of pH, viscosity, and particle counting. Integrated by Freeslate’s Lab Execution and Analysis software suite, the system allows for the control and data integration of a range of third-party analytics, including Dynamic Light Scatter, UV/VIS plate readers, and high pressure liquid chromatography.
Source: Freeslate
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.